Resverlogix to Host BETonMACE Webcast and Conference Call
September 26, 2019 19:04 ET
|
Resverlogix Corp
CALGARY, Alberta, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that, in connection with BETonMACE topline results, expected to be...
Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
September 23, 2019 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today the Late Breaking Science submission, regarding the primary results...
Resverlogix Provides Update on BETonMACE Phase 3 Trial
September 16, 2019 08:30 ET
|
Resverlogix Corp
Top-line results projected to be available on or about September 30, 2019 Number of MACE increases from 250 to greater than 275 CALGARY, Alberta, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Resverlogix...
Resverlogix Announces Annual and Special Meeting of Shareholders
August 22, 2019 17:24 ET
|
Resverlogix Corp
CALGARY, Alberta, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”)...
Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
August 14, 2019 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announces today that it will present at ESC Congress 2019, held this year in Paris,...
Resverlogix Announces Loan Reduction and Extension
August 02, 2019 12:02 ET
|
Resverlogix Corp
CALGARY, Alberta, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an amending agreement with Third Eye...
Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
July 15, 2019 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, July 15, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone (RVX-208)...
Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
July 08, 2019 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, July 08, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company’s...
Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
June 12, 2019 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, June 12, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company’s...
Resverlogix Announces Participation at Leading, International Scientific Conferences
June 10, 2019 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, June 10, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading, international scientific conferences...